Arsenite inhibits p53 phosphorylation, DNA binding activity, and p53 target gene p21 expression in mouse epidermal JB6 cells

Molecular Carcinogenesis

Volumn 45, Issue 11, 2006, Pages 861-870

  Tang, Faqing ^a   Liu, Guangming ^a   He, Zhiwei ^a   Ma, Wei Ya ^a   Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Arsenite; CK2; Epidermal mouse JB6 CI41 cells; p21; p53; UVB

Indexed keywords

ARSENIC TRIOXIDE; CASEIN KINASE II; COCARCINOGEN; PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER RISK; CELL STRAIN; CELL STRAIN JB6; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDERMIS CELL; GENE EXPRESSION REGULATION; GENE TARGETING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRANSACTIVATION; ULTRAVIOLET B RADIATION;

ANIMALS; ARSENITES; CARCINOGENS; CELL LINE; DNA; EPIDERMIS; MICE; MUTAGENS; ONCOGENE PROTEIN P21(RAS); PHOSPHORYLATION; PROTEIN BINDING; SERINE; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

ANIMALIA;

EID: 33750462388     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20245     Document Type: Article

References (51)

1. Guha Mazumder DN, Hague R, Ghosh N, et al. Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. Int J Epidemiol 1998;27:871-877.
2. Kadono T, Inaoka T, Murayama N, et al. Skin manifestations of arsenicosis in two villages in Bangladesh. Int J Dermatol 2002;41:841-846.
3. Karagas MR, Le CX, Morris S, et al. Markers of low level arsenic exposure for evaluating human cancer risks in a US population. Int J Occup Med Environ Health 2001;14:171-175.
4. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic in Utah: A cohort mortality study. Environ Health Perspect 1999;107:359-365.
5. EPA. National primary drinking water regulations; Arsenic and clarifications to compliance and new source contaminants monitoring. Fed Regist 2000;65:-38983.
6. Waalkes MP, Ward JM, Diwan BA. Induction of tumors of the liver, lung, ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: Promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers. Carcinogenesis 2004;25:133-141.
7. Burns FJ, Uddin AN, Wu F, Nadas A, Rossman TG. Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: A dose-response study. Environ Health Perspect 2004;112:599-603.
8. Chen H, Li S, Liu J, Diwan BA, Barrett JC, Waalkes MP. Chronic inorganic arsenic exposure-induces hepatic global and individual gene hypomethylation: Implications for arsenic hepatocarcinogenesis. Carcinogenesis 2004;25:1779-1786.
9. Sens DA, Park S, Gurel V, Sens MA, Garrett SH, Somji S. Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol Sci 2004;79:56-63.
10. Kayajanian GM. Arsenic, dioxin, and the promotional step in cancer creation. Ecotoxicol Environ Saf 2000;45:195-197.
11. Tsuchiya T, Tanaka-Kagawa T, Jinno H, et al. Inorganic arsenic compounds and methylated metabolites induce morphological transformation in two-stage BALB/c 3T3 cell assay and inhibit metabolic cooperation in V79 cell assay. Toxicol Sci 2005;84:344-351.
12. Germolec DR, Spalding J, Boorman GA, et al. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res 1997;386:209-218.
13. Rossman TG, Uddin AN, Burns FJ. Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol Appl Pharmacol 2004;198:394-404.
14. Pi J, He Y, Bortner C, et al. Low level, long-term inorganic arsenite exposure causes generalized resistance to apoptosis in cultured human keratinocytes: Potential role in skin co-carcinogenesis. Int J Cancer 2005;116:20-26.
15. Filippova M, Duerksen-Hughes PJ. Inorganic and dimethylated arsenic species induce cellular p53. Chem Res Toxicol 2003;16:423-431.
16. Yih LH, Lee TC. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res 2000;60:6346-6352.
17. Vogt BL, Rossman TG. Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts-A possible mechanism for arsenite's comutagenicity. Mutat Res 2001;478:159-168.
18. Vousden KH. p53: Death star. Cell 2000;103:691-694.
19. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
20. Salazar AM, Ostrosky-Wegman P, Menendez D, Miranda E, Garcia-Carranca A, Rojas E. Induction of p53 protein expression by sodium arsenite. Mutat Res 1997;381:259-265.
21. Hamadeh HK, Vargas M, Lee E, Menzel DB. Arsenic disrupts cellular levels of p53 and mdm2: A potential mechanism of carcinogenesis. Biochem Biophys Res Commun 1999;263:446-449.
22. Colburn NH, Former BF, Nelson KA, Yuspa SH. Tumour promoter induces anchorage independence irreversibly. Nature 1979;281:589-591.
23. Colburn NH, Wendel EJ, Abruzzo G. Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: Mitogen-resistant variants are sensitive to promotion. Proc Natl Acad Sci USA 1981;78:6912-6916.
24. Sun Y, Dong Z, Nakamura K, Colburn NH. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J 1993;7:944-950.
25. Dong Z, Lavrovsky V, Colburn NH. Transformation reversion induced in JB6 RT101 cells by AP-1 inhibitors. Carcinogenesis 1995;16:749-756.
26. She QB, Ma WY, Zhong S, Dong Z. Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. J Biol Chem 2002;277:24039-24048.
27. Huang C, Bode AM, Chen NY, et al. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res 2001;21:261-267.
28. Rosenberger SF, Bowden GT. Okadaic acid stimulated TRE binding activity in a papilloma producing mouse keratinocyte cell line involves increased AP-1 expression. Oncogene 1996;12:2301-2308.
29. Monick MM, Carter AB, Hunninghake GW. Human alveolar macrophages are markedly deficient in REF-1 and AP-1 DNA binding activity. J Biol Chem 1999;274:18075-18080.
30. Huang C, Ma WY, Li J, Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 1999;59:3053-3058.
31. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455:59-62.
32. Nuntharatanapong N, Chen K, Sinhaseni P, Keaney JF, Jr. EGF receptor-dependent JNK activation is involved in arsenite-induced p21Cip1/Waf1 upregulation and endothelial apoptosis. Am J Physiol Heart Circ Physiol 2005;289:H99-H107.
33. Kitamura K, Minami Y, Yamamoto K, et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000;14:1743-1750.
34. Scholz C, Wieder T, Starck L, et al. Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 2005;24:1904-1913.
35. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-3903.
36. Chen F, Lu Y, Zhang Z, et al. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 2001;276:11414-11419.
37. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 1996;15:6269-6279.
38. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-126.
39. Malkin D. The role of p53 in human cancer. J Neurooncol 2001;51:231-243.
40. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274:36031-36034.
41. Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene 2005;24:2899-2908.
42. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nature Rev Cancer 2004;4:793-805.
43. Hupp TR. Regulation of p53 protein function through alterations in protein-folding pathways. Cell Mol Life Sci 1999;55:88-95.
44. Gotz C, Scholtes P, Prowald A, Schuster N, Nastainczyk W, Montenarh M. Protein kinase CK2 interacts with a multiprotein binding domain of p53. Mol Cell Biochem 1999;191:111-120.
45. McKendrick L, Milne D, Meek D. Protein kinase CK2-dependent regulation of p53 function: Evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. Mol Cell Biochem 1999;191:187-199.
46. Bode AM, Dong Z. The paradox of arsenic: Molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 2002;42:5-24.
47. Bode A, Dong Z. Apoptosis induction byarsenic: Mechanisms of action and possible clinical applications for treating therapy-resistant cancers. Drug Resist Updat 2000;3:21-29.
48. Hamadeh HK, Trouba KJ, Amin RP, Afshari CA, Germolec D. Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol Sci 2002;69:306-316.
49. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 1996;10:1054-1072.
50. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998;273:1-4.
51. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.